Liver tumor

Medicines360 and DKT WomanCare Announce Strategic Partnership to Expand Access to the Hormonal IUD Avibela™

Retrieved on: 
Wednesday, January 31, 2024
SAN, Nausea, Clinical trial, Perforation, Birth, Fibroid, Internal bleeding, Liver failure, Infection, Artery, Pelvic pain, DKT International, Jaundice, Anticoagulant, Blood pressure, Ovarian cyst, Woman, Acne, Organization, Partnership, Endometritis, Angioedema, History, Abscess, Contraindication, DKT, Peritonitis, Rash, Coagulopathy, Dyspareunia, Inflammatory cytokine, Adhesion, Vomiting, Bacterial vaginosis, Headache, Bowel obstruction, IUS, Uterus, STI, Breast cancer, Miscarriage, Patient, Fertility, Sepsis, Marketing, Risk, Stroke, Organ, Streptococcus, Hormone-sensitive cancer, Liver tumor, Cyst, Intrauterine device, GAS, Pregnancy, PID, Social marketing, Vaginitis, Migraine, Myocardial infarction, Health, Brain, Birth control

"As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.

Key Points: 
  • "As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.
  • “DKT WomanCare looks forward to leveraging our global partnerships and commercial relationships to ensure every woman, regardless of income, can access affordable, high-quality contraception.
  • As the supplier of AVIBELA, Medicines360 will focus on providing quality assurance and regulatory oversight, as well as ensuring sustainable product supply to DKT WomanCare and global procurement agencies.
  • Together, Medicines360 and DKT WomanCare will meet the growing demand for quality-assured, affordable hormonal IUDs and help build a robust and sustainable global contraceptive market.

Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation

Retrieved on: 
Monday, January 8, 2024
IO, Liver tumor, Physician, Software, LTD, FDA, RAZ, Literature, Radiology, CECT, Patient, De novo, Medical imaging

REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- Techsomed Medical Technologies LTD is thrilled to announce that FDA has granted De Novo clearance for its BioTraceIO, a groundbreaking ultrasound-based liver ablation software - designed for Tissue Response Prediction.

Key Points: 
  • REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- Techsomed Medical Technologies LTD is thrilled to announce that FDA has granted De Novo clearance for its BioTraceIO, a groundbreaking ultrasound-based liver ablation software - designed for Tissue Response Prediction.
  • Ablation therapy, a minimally invasive treatment leveraging extreme temperatures, currently does not have tools available to predict the effect of ablation based on ultrasound.
  • BioTraceIO utilizes a unique computational algorithm to analyze ultrasound images captured during liver ablation treatment.
  • The integrated solution provides a comprehensive image-guided ablation visualization framework for eliminating guesswork typically associated with thermal ablation therapy.

World’s First Patients Treated With Novel Edison® Histotripsy System

Retrieved on: 
Friday, January 5, 2024
Medical Devices, Surgery, Hospitals, Clinical Trials, Health Technology, Biotechnology, University, Health, Education, Oncology, Liver, Metastasis, Cleveland Clinic, Science, Liver tumor, Division, Multimedia, Physician, FDA, Pain, Disease, MD, Doctor of Philosophy, Thomas Edison, Kidney, Patient, Medical imaging

In the same week Cleveland Clinic treated their initial patients suffering from liver tumors utilizing histotripsy.

Key Points: 
  • In the same week Cleveland Clinic treated their initial patients suffering from liver tumors utilizing histotripsy.
  • HistoSonics' image guided sonic beam therapy system uses proprietary technology and advanced imaging to deliver non-invasive, personalized treatments with precision and control.
  • The science of histotripsy uses focused sound energy to produce controlled acoustic cavitation that mechanically destroys and liquifies targeted tissue at sub-cellular levels.
  • By destroying targeted liver tumors, histotripsy opens the opportunities for patients to be downstaged and bridged for surgical resections and transplantation,” said Dr. Hernandez-Alejandro.

Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software

Retrieved on: 
Tuesday, September 5, 2023
CT, University, IO, Ablation, 3D, Liver tumor, De novo transcriptome assembly, Doctor of Philosophy, MRI, Magnetic resonance imaging, MD, Patient, Physician, Risk, Visual control, AI, FDA, Recurrence, Food, Safety, Medical device, Medical imaging

REHOVOT, Israel, Sept. 5, 2023 /PRNewswire/ -- Techsomed Ltd., a medical software innovator dedicated to enhancing clinical impact in ablation therapy, announced today that it has received 510(k) clearance from the USA Food and Drug Administration (FDA) for its VisAble.IO software intended to assist physicians in planning liver ablation procedures, and confirming ablation zones, with the goal of increasing treatment precision.

Key Points: 
  • REHOVOT, Israel, Sept. 5, 2023 /PRNewswire/ -- Techsomed Ltd., a medical software innovator dedicated to enhancing clinical impact in ablation therapy, announced today that it has received 510(k) clearance from the USA Food and Drug Administration (FDA) for its VisAble.IO software intended to assist physicians in planning liver ablation procedures, and confirming ablation zones, with the goal of increasing treatment precision.
  • Ablation Therapy is a preferred minimally invasive treatment that uses extremely high or low temperatures to destroy abnormal tissue.
  • VisAble.IO employs advanced computation and image registration to assist physicians in crucial steps of planning and assessing the ablation coverage of liver tumor.
  • This is a pivotal step forward in our journey of elevating ablation therapy into image guided ablation therapy and making it available for every patient everywhere".

Precision IR Performs First Outpatient Y-90 Radioembolization Procedure in an Office-Based Lab in Michigan

Retrieved on: 
Friday, June 2, 2023
Biotechnology, Health, Radiology, Practice Management, Oncology, P.C, Osteoarthritis, Radiation, Y-90, Hepatic artery proper, Half-life, Neoplasm, Liver tumor, Journal of Vascular and Interventional Radiology, Cancer, Prostate, Precision, Liver cancer, Blood, Knee pain, Interventional radiology, Go (programming language), Hospital, Patient, Observation, Growth, OBL, Trauma, Liver, Medical imaging

Precision IR, a Division of Michigan Healthcare Professionals, P.C., a medical practice specializing in vascular and interventional radiology, performed the first outpatient OBL (office-based lab) Y-90 radioembolization procedure in Michigan on Thursday, May 25, 2023.

Key Points: 
  • Precision IR, a Division of Michigan Healthcare Professionals, P.C., a medical practice specializing in vascular and interventional radiology, performed the first outpatient OBL (office-based lab) Y-90 radioembolization procedure in Michigan on Thursday, May 25, 2023.
  • To perform the procedure in an OBL setting, the facility must have the required imaging equipment and procedure rooms, along with the processes to safely handle nuclear materials.
  • Clinical experience has shown that the vast majority of Y-90 radioembolization patients do not need to be kept overnight for observation; they are able to return home shortly after the two-hour procedure.
  • “But cancer patients appreciate the option of having their treatment in a more relaxed and customer-focused environment.”
    Precision IR is now scheduling Y-90 radioembolization patients.

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Combination, MYC, Doctor of Philosophy, Hepatocellular carcinoma, Consistency, OEC, American Society of Clinical Oncology, Clinical trial, Liver tumor, Omega, NSCLC, Lung cancer, Immunotherapy, Messenger, ASCO, Liver, CD8, CBI, Annual general meeting, TME, Regional Security System, Standard of care, Therapy, IND, PD-L1, Tumor microenvironment, HCC, Society, Vaccine, Pharmaceutical industry

“The enhanced anti-tumor activity demonstrated in these preclinical data strongly support further investigation of MYC-targeting OECs in combination with clinically-validated approaches such as checkpoint blockade immunotherapies.

Key Points: 
  • “The enhanced anti-tumor activity demonstrated in these preclinical data strongly support further investigation of MYC-targeting OECs in combination with clinically-validated approaches such as checkpoint blockade immunotherapies.
  • MYC OECs downregulated expression of PD-L1 protein on the surface of HCC and NSCLC tumor cells in vitro.
  • The combination of MYC OEC and anti-PD-1 or anti-PD-L1 blockade significantly reduced tumor growth in a mouse xenograft liver tumor model compared to single agent treatment.
  • In immune-competent mouse allograft tumor models MYC OEC alone or in combination with CBI conferred anti-tumor immune memory.

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

Retrieved on: 
Thursday, February 16, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, Drug, Liver tumor, Uveal melanoma, Therapy, MDSC, Liver disease, Patient, Cholangiocarcinoma, Hepatocellular carcinoma, FACS, Ipilimumab, Nivolumab, Medical imaging, Pharmaceutical industry, MD

The presentation is available on the investor relations section of the Company’s website.

Key Points: 
  • The presentation is available on the investor relations section of the Company’s website.
  • TriSalus expects data in connection with higher doses by Q2 2023, in addition to data from a separate cohort that combines SD-101 with the combination of nivolumab and ipilimumab.
  • TriSalus is continuing to enroll patients in both PERIO™-01 and PERIO™-02 and is adding additional clinical sites in anticipation of Phase 2 programs in the second half of 2023.
  • Based on the initial data at the lower end of our SD-101 dose range in combination with checkpoint inhibition, we are eager for clinical results at higher dose levels.”

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

Retrieved on: 
Monday, November 21, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Communication, Clinical trial, Environment, Proxy, Drug, Acquisition, Mergers and acquisitions, Person, Maple Avenue/Maple Lane Historic District, Growth, Register, Risk, Name, Immunotherapy, Blood, Section 10 of the Canadian Charter of Rights and Freedoms, Liver tumor, Liver, XV, Form, Prospectus, 100,000, Neoplasm, TLR9, FACS, MTAC, Business, Form S-1, Tripura Merger Agreement, FDA, Sale, Business architecture, Registration statement, Pressure, XXV, Failure, CRIMINAL, Annual report, Therapy, Special, MDSC, Medtech, Myeloid-derived suppressor cell, Patient, Medical imaging, Pharmaceutical industry, Risk management, Security (finance), MD

The initial findings from these studies offer encouraging data supporting TriSalus proprietary Pressure-Enabled Drug Delivery (PEDD) method, said Steven C. Katz, MD, FACS, Chief Medical Officer at TriSalus.

Key Points: 
  • The initial findings from these studies offer encouraging data supporting TriSalus proprietary Pressure-Enabled Drug Delivery (PEDD) method, said Steven C. Katz, MD, FACS, Chief Medical Officer at TriSalus.
  • The Company expects PERIO 01 and PERIO 02 Phase 1 response data in December 2022.
  • The studies continue to enroll at higher SD-101 dose levels in combination with checkpoint inhibitors.
  • TriSalus is an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors.

Global Medical Imaging Equipment Markets, 2022-2026: Upsurge in Demand for Point Of Care Diagnostics, Emerging 4D & 5D Ultrasound Imaging Technology, & Cryogen-Free MRI Imaging System

Retrieved on: 
Tuesday, June 21, 2022
Helium, CAGR, Population, Industry, Education, GE Healthcare, Radiology, Siemens Healthineers, General Electric Company, COVID-19, Liver tumor, Google Images, Ageing, Technology, Kidney, Gallstone, Uterus, Philips, Government, PCOS, Samsung, Lists of countries and territories, Cancer, Company, Health status of Asian Americans, Hospital, Growth, Therapy, Breast cyst, Siemens, First Affiliated Hospital of Xinjiang Medical University, Surgeon, Artificial intelligence, Health, GE, Nature, Canon Medical Systems Corporation, Zhejiang University School of Medicine, Radiation, Death, MRI, Patient, Conditional sentence, Diagnosis, Pancreas, Awareness, Dentist, Rest, Hitachi, Income, Carestream Health, Fetus, Animal, Medical imaging, Healthcare, Medical device, Esaote, Asia-Pacific

In 2021, global medical imaging equipment market was valued at US$38.36 billion in 2021, and is expected to reach up to US$48.58 billion in 2026.

Key Points: 
  • In 2021, global medical imaging equipment market was valued at US$38.36 billion in 2021, and is expected to reach up to US$48.58 billion in 2026.
  • Medical imaging equipment has become a significant instrument for doctors, dentists, surgeons and physical therapists with the objective of offering better care for their patients.
  • Other than this, rapid rise in demand for point of care diagnostics is also providing growth opportunities to the market.
  • Furthermore, other notable trends such as 3D printing in medical imaging, emerging 4D & 5D ultrasound imaging technology and cryogen-free MRI imaging system would also provide significant growth opportunities to the market.

Global Medical Imaging Equipment Market Analysis Report 2022 - Impact of COVID-19 and Forecast up to 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Radiology, Health, Medical Devices, Helium, CAGR, Population, Industry, Education, GE Healthcare, Radiology, Siemens Healthineers, General Electric Company, COVID-19, Liver tumor, Google Images, Ageing, Technology, Kidney, Gallstone, Uterus, Philips, Government, PCOS, Samsung, Lists of countries and territories, Cancer, Company, Health status of Asian Americans, Hospital, Growth, Therapy, Breast cyst, Siemens, First Affiliated Hospital of Xinjiang Medical University, Surgeon, Artificial intelligence, Health, GE, Nature, Canon Medical Systems Corporation, Zhejiang University School of Medicine, Radiation, MRI, Death, Patient, Conditional sentence, Diagnosis, Pancreas, Awareness, Dentist, Rest, Hitachi, Income, Carestream Health, Fetus, Animal, Medical imaging, Healthcare, Medical device, Esaote, Asia-Pacific

The "Global Medical Imaging Equipment Market: Analysis By Product By End User Size and Trends with Impact of COVID-19 and forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Imaging Equipment Market: Analysis By Product By End User Size and Trends with Impact of COVID-19 and forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • In 2021, global medical imaging equipment market was valued at US$38.36 billion in 2021, and is expected to reach up to US$48.58 billion in 2026.
  • Growth Drivers: The aging population is a prominent growth factor of medical imaging market.
  • Global medical imaging equipment market is concentrated in nature, which place few of the players at the top.